Vine Ventures puts its profits on the line

The first obstacle was the investor himself. When Ryan Zurrer began exploring psychedelic businesses, he found people doing work he admired who grew wary as soon as they learned his profession. Venture capital carried baggage. In a field concerned with healing, the prospect of somebody collecting a large return could make the whole conversation seize up.

His response became the defining feature of Vine Ventures, the early-stage firm at vine.vc. It would invest in the emerging mental-health economy while promising to send part of its own upside back into it. The interesting question was whether that promise could be made concrete enough to change a founder’s calculation.

01 / The price of being believed

In a Third Wave interview, Zurrer described writing philanthropic checks before some of his commercial investments. He saw nonprofits doing valuable work and entrepreneurs wrestling with a practical dilemma: how to build a durable business without surrendering the purpose that brought them into the field.

Vine’s answer was its reciprocity pledge. Half the general partners’ carried interest, their share of investment profits, would support nonprofit work. Outside investors’ capital was a separate pot. Portfolio entrepreneurs and advisers would direct the philanthropic allocation, giving the people building the companies a say in where some of the resulting wealth went.

That decision had a cost: the partners committed part of their potential personal upside. It also changed the conversation. Zurrer said he had underestimated the effect on deal flow. A founder could assess an economic commitment alongside the investor’s good intentions.

“I dramatically underestimated the effect that that would have for deal flow”Ryan Zurrer, discussing reciprocity on Third Wave

02 / Follow the molecule downstream

Vine’s investment logic becomes clearer when the spotlight moves away from a single potential breakthrough drug. Someone must manufacture the ingredients. Someone must build the care infrastructure. Other companies may reach people through experiences that require no drug at all.

In his March 2021 essay, Zurrer singled out Psygen, a Canadian manufacturer of psychedelic active ingredients whose seed round Vine had led. The attraction was technical competence and a useful position in the supply chain. A manufacturer could supply an industry whether its eventual medicines were dominated by patents or by generics.

Vine wanted teams with scientific depth and businesses capable of reaching many people. This offers founders a useful test: explain the bottleneck your company removes, the expertise required to remove it, and why the work remains valuable under competing versions of the future.

03 / A trip without the molecule

Consider TRIPP. In June 2021, Vine and Mayfield co-led an $11 million financing for the immersive wellness company. Its platform used visual environments, sound and interaction to support emotional wellbeing. The announced uses of the money included research, hiring and expanding distribution across platforms.

At the time, TRIPP reported delivering more than two million sessions on Oculus and PlayStation VR. That was usage, rather than evidence that every session produced a clinical benefit. It nevertheless showed how an investor associated with psychedelics could back a product people experienced through a headset.

Today, TRIPP describes a broader offering spanning mobile, XR and its Kōkua AI companion. Consumers can explore the product directly; they do not become customers of Vine. For the fund, the relationship runs through investment in the company. Its everyday users sit one step further along the chain.

04 / The $70 million question

The financing experiment grew more ambitious in December 2021, when MAPS and Vine announced the Regenerative Financing Vine. The proposed $70 million vehicle would support MDMA-assisted therapy research and access infrastructure for PTSD, with investors paid through a share of future drug revenue.

The published terms, corrected in February 2022, specified 6.1% of North American MDMA revenue for eight years after initial sales. Once investor returns reached twice the original principal, 20% of subsequent revenue-share receipts would go back to MAPS. Further milestones increased that proportion. Vine said it would take no fees or carried interest on this particular vehicle.

The distinction matters. The reciprocity pledge concerned the partners’ profits across their venture approach. This deal waived Vine’s compensation on a specific structure. And $70 million described the announced financing plan; it was not a reported company valuation or proof of the full amount reaching its destination.

05 / A contract cannot approve a drug

In January 2024, MAPS Public Benefit Corporation became Lykos Therapeutics and announced a Series A exceeding $100 million, including conversion of earlier notes. Vine appeared among the participating investors. This was a separate financing event from the 2021 revenue-sharing announcement.

Then the regulatory path stalled. On August 9, 2024, Lykos announced that the FDA could not approve its application on the submitted evidence and had requested another Phase 3 study. The failure was specific: the application had not cleared the approval standard. Inventive financing could not resolve that scientific and regulatory problem.

The implication for a future-sales agreement is straightforward. Without commercial sales, the anticipated revenue stream cannot begin. Investors need time, capital and tolerance for that uncertainty. Founders need a funding structure that remains workable when the launch calendar slips.

06 / Put the promise in the terms

Vine occupies a particular corner of venture capital: early-stage mental health and wellness, with reciprocity built into its stated economics. It offers entrepreneurs capital and a point of view about how the gains should circulate. Patients encounter the resulting products and services through separate businesses.

The portable lesson is to inspect the allocation of money and decision-making power. Ask who benefits, who decides and what happens before revenue arrives. A structure like Vine’s depends on investment gains to generate philanthropic carry, and a royalty deal depends on sales. Those conditions deserve the same attention as the promise.